Back

A Phase 2 Trial of Trientine for Hypertrophic Cardiomyopathy

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Late-Breaking Clinical Science: spectrum of cardiomyopathies Hypertrophic Cardiomyopathy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Professor Christopher Miller

University of Manchester, Manchester (United Kingdom of Great Britain & Northern Ireland)

3 More presentations in this session

Presentation thumbnail
EMORI-HCM Electro-Mechanically Optimised RVP For oHCM
Doctor J. Mohal (London, GB)
Slides Video
Presentation thumbnail
REDWOOD-HCM, SEQUOIA-HCM and FOREST-HCM trials: Incidence and impact of atrial fibrillation in oHCM with aficamten
Doctor A. Masri (Portland, US)
Slides Video
Presentation thumbnail
Initial findings from MaesTTRo
Doctor M. Grogan (Rochester, US)
Slides Video

Access the full session

Session thumbnail
Late-Breaking Clinical Science: spectrum of cardiomyopathies
Video

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Efficacy and safety of long-term treatment with aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy: results from FOREST-HCM
thumbnail
Congress Presentation
CIRRUS­HCM: A multiple-dose phase 2 study of safety, tolerability, and effects on hemodynamics and functional capacity of the novel cardiac sarcomere modulator EDG-7500 in hypertrophic cardiomyopathy
thumbnail
Congress Presentation
Effect of Aficamten Compared with Metoprolol on Cardiac Structure and Function in Symptomatic Obstructive Hypertrophic Cardiomyopathy: A pre-specified analysis of MAPLE-HCM

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources